What Is Hematopoietic Stem Cell Transplantation?

Hematopoietic Stem Cell Transplantation (HSCT) is a common treatment for hematologic disorders. For patients already diagnosed with malignant hematologic diseases, HSCT offers an effective therapeutic option and the potential for complete cure. But what exactly is hematopoietic stem cell transplantation? The following section provides an explanation.

What Is Hematopoietic Stem Cell Transplantation?

Hematopoietic stem cell transplantation involves high-dose chemotherapy and/or radiotherapy to ablate the recipient’s diseased or malignant cells, followed by infusion of autologous or allogeneic hematopoietic stem cells to reconstitute the recipient’s hematopoietic and immune systems. Currently, HSCT is widely applied in the treatment of malignant hematologic diseases, severe aplastic anemia, inherited metabolic disorders, and certain solid tumors, achieving favorable clinical outcomes. Hematopoietic stem cells possess the capacity for self-renewal and differentiation into all mature blood cell lineages, thereby sustaining lifelong hematopoiesis. These stem cells can be harvested from bone marrow, peripheral blood, or umbilical cord blood. With advances in modern medicine, HSCT has become an essential and highly effective clinical therapy. However, both patients with benign and malignant diseases may face disease relapse post-transplantation. Moreover, the chemotherapy and/or radiotherapy used during HSCT may impair fertility and carry a potential risk of secondary malignancy.

Knowledge Expansion: Risks Associated with Hematopoietic Stem Cell Transplantation

1. Infection

Following HSCT, patients experience significant immunosuppression, markedly increasing their susceptibility to infection—occurring in 50%–80% of cases. Infectious complications may affect any organ system and may arise from procedural complications, reactivation of latent pathogens, or exposure to novel environmental pathogens. Causative agents include bacteria, fungi, viruses, and parasites. Infection remains one of the leading factors affecting long-term survival after transplantation.

2. Graft Failure

Graft failure is among the most serious early complications of HSCT. It occurs when the transplanted graft fails to engraft, resulting in failed hematopoietic reconstitution. Clinically, this manifests as severe pancytopenia accompanied by hypocellular or aplastic bone marrow, along with life-threatening infectious and hemorrhagic complications that are difficult to manage and associated with high mortality. However, with continuous improvements in transplant techniques, the incidence of graft failure has decreased to below 5%, and in some centers, even lower.

The above provides an overview of hematopoietic stem cell transplantation. We hope this information is helpful to you.